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Clear cell adenocarcinoma (CCC) is generally thought to originate from ovarian, endometrial, or renal tissue. A CCC
of the peritoneum (CCAP) is an extremely rare medical condition and is associated with a poor prognosis. To date,
only 10 cases of CCAP have been reported, of which half resulted in death or recurrence within 6 months after
initial treatment because CCAP is commonly resistant to multiple drugs. In this report, we present a case of CCAP
of the pouch of Douglas coexisting with an endometriosis and we offer a review of the related literature.
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Clear cell adenocarcinoma of the peritoneum is an ex-
tremely rare medical condition with poor prognosis. Be-
cause of its reality, no standard treatment has been
established. Here, we report a case with primary clear
cell adenocarcinoma in the pouch of Douglas treated by
debulking surgery followed by chemotherapy.Case
A 59-year-old postmenopausal woman, gravida 2, para
2, was referred to our hospital for the treatment of a
pelvic mass. Her initial complaints were appetite loss
and 12 kg weight loss over 3 months. Her past medical
history was unremarkable, except for an appendectomy,
and her gynecological medical history included admin-
istration of a gonadotropin releasing hormone agonist
for the treatment of adenomyosis manifesting as severe
dysmenorrhea.
On her first visit, a vaginal ultrasound revealed a hetero-
geneous solid mass with cystic areas which was located ap-
proximately 6 cm deep within the pelvis (Figure 1a). Pelvic
examination revealed a firm adhesion between the tumor
and uterus. Magnetic resonance imaging (MRI) of the pel-
vis revealed an 8 cm heterogeneous mass located on the
posterior (intestinal) surface of the uterus, with possible* Correspondence: yoshino@gyne.med.osaka-u.ac.jp
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unless otherwise stated.rectal invasion (Figure 1b). Uterine adenomyosis was also
detected by MRI. Fluorodeoxyglucose (FDG) positron
emission tomography–computed tomography revealed a
mass on the posterior surface of uterus with FDG uptake in
the nodules adjacent to right side of the mass and in the
pelvic and obturator lymph nodes. The serum level of can-
cer antigen (CA) 125 was slightly elevated to 76 U/mL
(normal limit: 35 U/mL), whereas CA19-9 and carcinoem-
bryonic antigen (CEA) levels were within normal ranges.
Taken together, we made a preoperative diagnosis of a left
ovarian malignant tumor. During surgery, surprisingly, the
tumor was located in the pouch of Douglas and was found
to not originate from the ovary (Figure 2a and b). The
tumor was adherent to the uterus at the left uterosacral
ligament and had also invaded the rectum. Both ovaries ap-
peared normal. During surgery, the tumor capsule was rup-
tured; because of this, the tumor was removed together
with the rectum, uterus and both ovaries. Total abdominal
hysterectomy, bilateral salpingo-oophorectomy, partial
infracolic omentectomy, pelvic lymphadenectomy, and low
anterior resection of the rectum were performed. There
were no macroscopic residual tumors, thus the procedures
performed were considered an optimal surgical treatment.
On macroscopic evaluation, a multilobular cyst with
a yellowish necrotic solid part was found on the cut
surface of the tumor (Figure 3a). The tumor had in-
vaded the uterine cervix and rectum, up to the level of
the mucosa. Both ovaries were visually tumor free.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Clinical imaging of the tumor. a. Vaginal ultrasonography revealed a 6 cm heterogeneous tumor located in the pouch of Douglas,
with a suspected left ovarian involvement. b. T2-weighted MRI revealed an 8 cm heterogeneous tumor located at the posterior (intestinal) surface
of the uterus, with a suspected rectal invasion.
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cell adenocarcinoma. Glandular and papillary struc-
tures were lined by clear cells and a hobnail arrange-
ment of cells within the glands was found (Figure 3b).
The clear cells contained eosinophilic cytoplasm.
Immunochemical staining for cytokeratin 7 was posi-
tive, whereas staining for cytokeratin 20, caudal-type
homeobox protein 2, and estrogen receptor were nega-
tive. These results indicated that the tumor did not ori-
ginate from the rectum. Microscopically, tumor cells
were not observed in either ovary. Lymphatic vessel in-
vasion was observed in the invasive area of the rectum,
and 3 of 3 resected pararectal lymph nodes (#251) were
involved by the tumor. On the other hand, there were no
metastases in 28 of resected regional pelvic lymph nodes.
An adenomyoma was found in the uterus and endome-
triotic lesions were found at the peritoneum near the
tumor. Thus, the tumor was diagnosed as CCAP with
endometriosis. Postoperative staging was FIGO stage IIB
(pT2bN0M0).Figure 2 Image of the operation. a and b. Laparotomy revealed that the
pouch of Douglas. There was a strong adhesion between the tumor and reSix courses of combination chemotherapy with pacli-
taxel and carboplatin (TC) as adjuvant therapy was
planned. At 3 months after the primary surgery, the pa-
tient presented with strangulated ileus, which was cor-
rected by a second surgery. No recurrent disease was
observed in the abdomen at the surgery. Then, the pa-
tient completed the planned adjuvant therapy and has
remained well with no evidence of disease 10 months
after the primary surgery.
Discussion
Primary peritoneal carcinoma was first described by
Swerdlow in 1959 [1]. The Gynecologic Oncology group
defines the diagnostic criteria for primary peritoneal
carcinoma, where both ovaries are of normal size, with
an extraovarian involvement greater than the surface
ovarian involvement [2]. Our case met this criterion
and was histologically diagnosed as CCC.
To investigate reports of the incidence of CCAP, we
performed a search of the PubMed database using thetumor did not originate from the ovary, and it was located in the
ctum.
Figure 3 Gross and microscopic appearance of the tumor. a. A photograph of the cut surface of the tumor. A multilobular cyst with a
yellowish necrotic solid part was observed. Both ovaries were normal. b. Histopathological features of the tumor. Clear cells lined the glandular
and papillary structure. A hobnail arrangement of the cells was seen (hematoxylin and eosin; original magnification: ×400).
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The search was limited to the English literature and
CCAP cases. We identified 10 cases that are summa-
rized in Table 1 [3-12]. These limited cases were
reviewed to provide characteristics of CCAP and iden-
tify potentially effective treatments. As summarized in
Table 1, 10 of the 11 cases (including our case) were ini-
tially treated by debulking surgery. Complete resection
was performed in six cases and the residual tumor size
was >2 cm in four cases. Eight cases received chemo-
therapy (seven postoperatively and one with primary
chemotherapy). The chemotherapy regimens performed
were TC [6,12], irinotecan hydrochloride + cisplatin
(CPT-P) [9], and cyclophosphamide + carboplatin + cis-
platin (CCP) [6].
We offered TC combination chemotherapy to our
patient. One report had found that a TC combination
therapy was effective for the treatment of CCAP. Out-
comes were poor in five cases. Of these, three patients
died within 6 months, and disease recurrence had
occurred in two cases at 4 months and 32 months,
respectively, after the initial therapy [6,8-11]. Three
patients died within 6 months and each had a re-
sidual tumor of >2 cm [5,7,9]. Early recurrence oc-
curred in the inoperable patients. The characteristic
features of the cases with particularly poor prognosis
were large residual tumors after primary surgery and
inoperability. On the other hand, there were three
cases with relatively good prognosis [8,9,11]. The
primary features of these cases were having had an
optimal or complete debulking surgery followed by
chemotherapy.
CCAP can closely resemble ovarian clear cell ade-
nocarcinoma (OCC) and it is difficult to distinguish
CCAP from OCC by preoperative imaging alone, espe-
cially if the tumor is located in the pelvis close to the
ovary or uterus, even though the radiological features of
CCAP have been reported in some cases. One report
cited a multicystic mass with a multiseptate appearanceand a heterogeneous solid part arising from the periton-
eum, suggesting the occurrence of a CCAP [12].
In our case, we did not observe such features and
we were unable to determine whether the pelvic
tumor originated from the peritoneum. We recom-
mend further imaging studies to establish a definitive
diagnosis of CCAP. An endometriosis coexisted with
the CCAP in our case. CCC is seen most frequently
in the ovary and is often associated with pelvic
endometriosis [6], as an association with endometri-
osis has been well established [9]. CCC occasionally
develops from extraovarian endometriosis [9,13].
There are several reports of CCAP cases with coex-
isting endometrial lesions. In some reports, endomet-
riosis was a required precursor of CCC in peritoneal
locations. However, others found that the tumor
arose de novo from the peritoneum [4]. The patho-
genesis of carcinoma coexisting with endometriosis
has not been fully elucidated. In past reports, two
possible theories for the association of carcinoma
and endometriosis were mentioned. These theories
included a genetic defect in already existing en-
dometriosis or a defect in the immune response of
patients with endometriosis that leads to the pro-
gression of endometriosis to subsequent malignant
transformation [2]. Hence, the pathogenesis of CCAP
associated with endometriosis remains controversial.
The pathogenesis of peritoneal serous carcinoma is
similar to that of ovarian cancer and may be de-
pendent on its origin from ovarian tissue remnants
in the peritoneum remaining from embryonic deve-
lopment or from the mesoderm that gives rise to
both the ovarian epithelium and peritoneum [14].
Therefore, female pelvic and abdominal mesothelium
may give rise to primary peritoneal carcinoma re-
sembling ovarian cancer [5]. In addition to these re-
ports, non-serous carcinoma of the peritoneum has
also been reported [15]. Therefore, CCAP may arise
de novo from the peritoneum.
Table 1 Summary of clear cell adenocarcinoma of the peritoneum











2 Lee et al. [4] 67 6 cm Concurrent EMA G1
of Ut (stageIb)
No DS+TAH+BSO >2 cm NA
Pelvic
3 Tziortzioti et al. [5] 62 0.5-2 cm Concurrent CCC in EP No DS+TAH+BSO +OM followed by
CHT (6 cycles, regimen NA)
>2 cm DOD at 6 mo
Peritoneal and omental
4 Ichimura et al. [6] 45 NA Both Ov EM Yes DS+TAH+BSO followed by CHT
(3 cycles of CPA,CDDP, CBDCA)
None ROD at 32 mo
Pelvic
5 Hama et al. [7] 53 NA EM Yes DS+BSO followed by CHT (regimen NA) >2 cm DOD at 5 mo
Ascites and small peritoneal solid
lesions
6 Terada et al. [8] 49 3 cm, 2 cm Past EMA G3 of Ut
(TAH+BSO)
No DS None NED at 6 mo
Gastric peritoneal, splenic hilus
7 Takano et al. [9] 53 5 cm None No DS followed by CHT (1 cycle of
CPT-11,CDDP, 1 cycle of TC)
>2 cm DOD at 5 mo
Upper abdomen between liver and
diaphragm and omentum
8 Takano et al. [9] 66 15×20 cm None No DS+TAH+BSO+OM+PLD+PAD followed
by CHT (6 cycles of CPT-11, CDDP)
None NED at 20 mo
Infracolic omentum and peritoneum
of right abdominal wall
9 Matsuo et al. [10] 37 14×13 cm EM Yes DS followed by CHT (6 cycles of TC),
Secondary devulking surgery
None ROD at 18 mo
Abdominal scar of EM surgery
10 Muezzinoglu et al.
[11]
54 25 cm Peritoneal EM Yes DS+TAH+BSO following by CHT
(regimen NA)
None NED at 12 mo
Abdominal
11 Johnson et al. [12] 54 5.6×3.7×3.5 cm 3xMMs, TAH+BSO for LM
and menorrhagia
No CHT (6 cycles of TC) followed by EBR
followed by the interstitial HDR BT boost
<2 cm ROD at 4 mo
proximal vagina and vaginal cuff
12 This report 59 7 cm AM, EM Yes DS+TAH+BSO+PLD followed
by CHT (6 cycles of TC)
None NED at 5 mo
Pelvic (pouch of douglas)
EM, endometriosis; Ov, ovary; Ut, uterus; AM, adenomyosis); EH, endometrial hyperplasia; EP, endometrial polyp; LM, leiomyoma; EMA, endometrial adenocarcinoma; CCC, clear cell adenocarcinoma, MM, myomectomy;
DS, debulking surgery; PLD, pelvic lymph node dissection; PAD, para-aortic lymph node dissection; OM, omentectomy; CHT, chemotherapy; RT, radiotherapy; EBR, external beam radiotherapy; BT, brachytherapy;
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Here, we report a case of primary clear cell adenocar-
cinoma arising from the pouch of Douglas. Although
10 similar cases have been reported, there is as yet no
established treatment regimen for this disease. Combin-
ation chemotherapy with debulking surgery has been sug-
gested for the treatment of residual tumors <2 cm with
postoperative chemotherapy, such as TC or CPT-P. To es-
tablish an effective treatment regimen for CCAP, a review
of a larger number of cases is still needed.
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